compliance issues reimbursing glp-1 weight loss treatments multiple states FDA issued 25 warning letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of GLP-1 Weight Loss Drugs: Coverage

Major dietary protein sources and risk of coronary heart disease in women

We need them because the FDA approval pathway only makes economic sense for blockbuster drugs that will sell millions of prescriptions

They may or may not have comorbidities, but would likely find some health benefits from losing weight via semaglutide treatment

Youre making a different trade-off

Retatrutide engages GLP-1R, GIPR, and GCGR with differential but meaningful potency at each site, producing a composite pharmacodynamic signal not achievable with single or dual agonists

doi: 10.1016/j.ajpath.2014.10.009 134 Veses-GarciaM.LiuX.RigdenD